Implementing iPSC Technology: Case studies of iPSC-tissue cell use in disease modeling and drug discovery

Case studies on deriving iPSCs from clinical and non-clinical populations and using iPSC-tissue cells in disease modeling and drug discovery.<br>Induced pluripotent stem cell (iPSC) technology is having a positive impact on drug discovery efforts through recent advances in generating iPSCs from both individuals and targeted populations as well as creating relevant iPSC-based human disease models. This presentation will provide data on the progress and process of two large-scale reprogramming efforts and several iPSC-based disease models being used within the Pharmaceutical industry. Population-based reprogramming efforts through the California Institute of Regenerative Medicine (CIRM) and National Heart, Lung, and Blood Institute (NHLBI), are generating ~3000 and ~250 donor lines across healthy and disease backgrounds. These iPSC clones will be deposited into publically accessible biobanks for further use by the research community. Additional case studies will be presented illustrating the utility and implementation of iPSC-based cardiac and neuronal genetic and environmental disease models in phenotypic screens. In summary this presentation will provide an overview of how iPSC technology brings human biology and diversity into drug discovery